secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neuphoria Therapeutics Inc. (NEUP)
CIK:        0001191070
Form:       8-K
Filed at:   2025-10-27T23:59:59+00:00
Accession:  0001213900-25-102607
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 3.03, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neuphoria adopts poison pill after investor accumulates >20%; launches strategic review
--------------------------------------------------------------------------------

- Rights plan triggered if any entity acquires 15%+ beneficial ownership without board approval.
- Adopted after an individual investor disclosed >20% ownership as of Oct 23, 2025.
- Rights expire Oct 27, 2026; no dead-hand/slow-hand provisions.
- Board also evaluating strategic alternatives to maximize stockholder value.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1191070/000121390025102607/0001213900-25-102607-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1191070/000121390025102607/ea0262561-8k_neuphoria.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-102607

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer